Langballe, Rikke
Cronin-Fenton, Deirdre
Dehlendorff, Christian
Jensen, Maj-Britt
Ejlertsen, Bent
Andersson, Michael
Friis, Søren
Mellemkjær, Lene
Article History
Received: 13 April 2018
Revised: 6 August 2018
Accepted: 14 August 2018
First Online: 24 October 2018
Competing interests
: Bent Ejlertsen has received research grants to his institution from Novartis, Roche and NanoString outside the submitted work. Maj-Britt Jensen has received personal fees from AstraZeneca and travel support from AstraZeneca, Novartis and Celgene outside the submitted work. Lene Mellemkjær has an immediate family member employed at Novo Nordisk, and has an immediate family member who owns stocks in Novo Nordisk. The remaining authors declare no competing interests.
: The study was approved by the Danish Data Protection Agency (J.no. 2012-41-0284). In Denmark, approvals from Ethical Committees are not required for register-based studies that do not involve biological samples.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).